General Updates

September 11, 2026 To To The Listing Department, The Corporate Relations Department, National Stock Exchange of India Limited BSE Limited NSE Symbol: VIJAYA BSE Scrip Code: 543350 Dear Sir/Madam, Sub: Investor Presentation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Strategic Acquisition / Execution of Business Transfer Agreement (BTA) Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in continuation of our earlier disclosure dated September 11, 2026 regarding the approval/execution of the Business Transfer Agreement (BTA) for the 100% acquisition of the integrated diagnostic business undertaking of Arya Wellness Centre, Guwahati, Assam on a slump sale basis from NEMRIL HRPL JV (North Eastern Medical Research Institute Limited – Hexagon Research Private Limited JV), we are enclosing herewith a copy of the Investor Presentation detailing the rationale, financial highlights, and strategic synergy of the said acquisition. Please take the information on record. Thanking you, For Vijaya Diagnostic Centre Limited Narasimha Raju K A Chief Financial Officer Encl.: As Above Acquisition of Integrated Diagnostic Business (Arya Wellness Centre) in Guwahati, Assam September 11, 2026 Q2 & H1 FY25 Earnings Presentation, November 07, 2024 Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Vijaya Diagnostic Centre Limited (the ‘Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the Company’s ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. All Maps used in the Presentation are not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness. About Arya Wellness Centre Business Overview FY26 Financial Performance ▪ Leading B2C focused integrated diagnostic centre in Guwahati, Assam serving entire North-East market INR 260 Mn ▪ Founded in 2021 as a Joint Venture / AOP between North Revenue from Operations (1) Eastern Medical Research Institute Ltd. (NEMRIL), which operates Arya Hospital, a leading multispecialty hospital in Guwahati, and Hexagonal Research Pvt. Ltd. (HRPL), representing a group of reputed doctors. INR 56 Mn | 21.4% INR 25 Mn | 9.5% ▪ The AOP operates under the brand “Arya Wellness Centre” from EBITDA (2) | EBITDA Margin % PAT (3) | PAT Margin % a single, well-equipped facility strategically located on GS Road, Guwahati’s key healthcare hub, and supported by a central reference laboratory ▪ Business Mix: Adv Radiology: 35%, Basic Radiology: 9%, Adv Key Metrics Pathology: 16%, Basic Pathology: 40% ▪ 85% + business comes from B2C due to strong pedigree of doctors both in pathology and radiology 44% | 56% 200+ Radiology | Pathology Daily FF Modalities 1 | 1 7% MRI CT Scan Ultrasound Neurology Cardiology Centre | Lab Home Collection % Gastro X-Ray Mammogram Endoscopy Laboratory 1. Excluding OPD consultation fee 2. IND AS EBITDA 3. IND AS adjusted PAT (Excluding Other Income, Finance Cost and considering Vijaya’s tax rate) Brief on the Promoters Dr. Bijoya Goswami (NEMRIL) Dr. Anup Das (HRPL) Dr. Pratap Kakati (HRPL) ✔ 40+ years of entrepreneurial ✔ 20+ yrs of post MD experience ✔ 20+ years of experience in experience ✔ MD in Radiology – PGIMER, Histopathology and Cytology ✔ Founder & MD, Arya Hospital Chandigarh ✔ MD in Pathology – AIIMS, Delhi Dr. Anil Kumar Agarwala Dr. Palash Jyoti Das (HRPL) (HRPL) ✔ 20+ yrs of post MD experience ✔ 20+ yrs of experience ✔ MD & SR in Interventional ✔ Diploma in Clinical Pathology Radiology – PGIMER, (DCP) from Assam Medical Chandigarh College & Hospital (AMCH) Transaction Consideration and Potential Timelines for the Closure Transaction at a Glance Indicative Transaction Timelines TRANSACTION CONSIDERATION ~₹46 Cr 10 Sep 2026 ~Nov / Dec 2026(2) Slump Sale 100% (BTA) CP Satisfaction Business Transfer BTA Signing Business acquisition Transaction structure & Transition / Closing ~8-9x Internal Transaction Completion and CP Completion announced operational handover EBITDA(1) Accruals Valuation Consideration The acquisition is EPS accretive right from the onset and provides us with an established and profitable operating base in Guwahati while maintaining our focus on capital efficiency and return thresholds 1. Adjusted FY26 IND AS EBITDA 2. Timelines are indicative and subject to satisfaction/waiver of conditions precedent and other closing requirements. Strategic Rationale for the Acquisition Guwahati is a natural extension to our growing presence in West Bengal and provides us with an attractive gateway to the wider North East region Provides immediate access to established operating platform with existing infrastructure, clinical capabilities & recognized local presence Specializes in High-End Imaging, Interventional Procedures and Histopathology work with an established B2C customer base Located strategically at the heart of Healthcare Infrastructure of Guwahati Reputed & Renowned Clinicians across pathology & radiology driving B2C business Healthy Financials with ~80% Gross Margin and ~21% EBITDA margin (1) 1. IND AS EBITDA Margin Management Commentary Our entry into Guwahati represents another important milestone in Vijaya’s journey towards building a high-quality integrated diagnostics platform. Guwahati is a natural strategic extension of our growing presence in West Bengal and provides us with an attractive gateway to the North-East. Arya Wellness Centre has been built on an ethos that closely aligns with Vijaya’s philosophy of delivering high-quality diagnostics with a strong focus on patient experience and co [Showing first 8,000 characters — download PDF for full document]